<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Shionogi & Co., Ltd. — News on 6ix</title>
<link>https://6ix.com/company/shionogi-and-co-ltd</link>
<description>Latest news and press releases for Shionogi & Co., Ltd. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 08 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/shionogi-and-co-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d6212ebeedb30cb6fc2a40.webp</url>
<title>Shionogi & Co., Ltd.</title>
<link>https://6ix.com/company/shionogi-and-co-ltd</link>
</image>
<item>
<title>Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/shionogi-receives-contract-with-us-government-through-bardas-project-bioshield-to-enhance-national-preparedness-for-drug-resistant-bacterial-threats</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/shionogi-receives-contract-with-us-government-through-bardas-project-bioshield-to-enhance-national-preparedness-for-drug-resistant-bacterial-threats</guid>
<pubDate>Wed, 08 Apr 2026 12:30:00 GMT</pubDate>
<description>OSAKA, Japan, April 08, 2026--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi Inc., a New Jersey-based subsidiary of Shionogi, has been awarded a contract through the Biomedical Advanced Research and Development Authority’s (BARDA) Project BioShield related to Fetroja® (cefiderocol) as a critical countermeasure against difficult-to-treat Gram-negative bacterial infections and pathogens that present a h</description>
</item>
<item>
<title>ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-Producing Enterobacterales Infections</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/escmid-global-2026-shionogi-presents-new-real-world-data-highlighting-clinical-effectiveness-of-fetrojarfetcrojar-cefiderocol-in-mbl-producing-enterobacterales-infections</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/escmid-global-2026-shionogi-presents-new-real-world-data-highlighting-clinical-effectiveness-of-fetrojarfetcrojar-cefiderocol-in-mbl-producing-enterobacterales-infections</guid>
<pubDate>Tue, 07 Apr 2026 12:30:00 GMT</pubDate>
<description>OSAKA, Japan, April 07, 2026--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") presents new real-world data evaluating Fetroja®/Fetcroja® (cefiderocol), an innovative siderophore cephalosporin, in adults with confirmed MBL-producing Enterobacterales infections at the 36th Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in Munich, 17th-21st April, 2026.1</description>
</item>
<item>
<title>Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/shionogi-completes-acquisition-of-all-rights-to-radicava-edaravone</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/shionogi-completes-acquisition-of-all-rights-to-radicava-edaravone</guid>
<pubDate>Wed, 01 Apr 2026 23:30:00 GMT</pubDate>
<description>OSAKA, Japan, April 01, 2026--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that we have completed the transfer of all rights for RADICAVA (edaravone), including intellectual property rights and sales rights, in major countries and regions to our company from Tanabe Pharma Corporation. Transfer of rights in additional countries and regions is forthcoming. The acquisition and integration of RADICAVA team members, p</description>
</item>
<item>
<title>Apnimed Announces Strategic Monetization of Shionogi-Apnimed Sleep Science (SASS) Joint Venture Stake for $150M and Royalties, Strengthening Focus on its Wholly-Owned OSA Program, AD109</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/apnimed-announces-strategic-monetization-of-shionogi-apnimed-sleep-science-sass-joint-venture-stake-for-dollar150m-and-royalties-strengthening-focus-on-its-wholly-owned-osa-program-ad109</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/apnimed-announces-strategic-monetization-of-shionogi-apnimed-sleep-science-sass-joint-venture-stake-for-dollar150m-and-royalties-strengthening-focus-on-its-wholly-owned-osa-program-ad109</guid>
<pubDate>Tue, 24 Mar 2026 12:00:00 GMT</pubDate>
<description>Apnimed, Inc., a pharmaceutical company developing an oral drug product candidate, AD109, that is designed to address a root cause of obstructive sleep apnea (OSA), today announced that Shionogi & Co. Ltd (Shionogi) have entered into a definitive agreement for Shionogi to acquire Apnimed's 50% ownership of Shionogi-Apnimed Sleep Science, LLC (SASS). SASS is a joint venture initially established in 2023, and upon the closing of this transaction, SASS will be wholly-owned by Shionogi.</description>
</item>
<item>
<title>ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/viiv-healthcare-presents-pipeline-data-for-two-investigational-hiv-treatment-therapies-with-potential-for-twice-yearly-dosing</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/viiv-healthcare-presents-pipeline-data-for-two-investigational-hiv-treatment-therapies-with-potential-for-twice-yearly-dosing</guid>
<pubDate>Wed, 25 Feb 2026 19:00:00 GMT</pubDate>
<description>LONDON, February 25, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data from its phase 1 study of long-acting formulations of VH184, the first, third-generation integrase strand transfer inhibitor (INSTI) in development for HIV.1 Results show a single-dose injection could maintain drug levels for up to six months. In-vitro data from a separate study demonstrate improved potency and an enhanced resistance</description>
</item>
<item>
<title>ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/viiv-healthcare-reports-positive-12-month-data-showing-investigational-bnab-lotivibart-n6ls-maintains-high-levels-of-viral-suppression-in-long-acting-hiv-treatment-regimen</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/viiv-healthcare-reports-positive-12-month-data-showing-investigational-bnab-lotivibart-n6ls-maintains-high-levels-of-viral-suppression-in-long-acting-hiv-treatment-regimen</guid>
<pubDate>Wed, 25 Feb 2026 19:00:00 GMT</pubDate>
<description>LONDON, February 25, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced positive 12-month interim efficacy and tolerability data from the phase IIb EMBRACE study.1 In adults living with HIV on stable therapy, a regimen of lotivibart (N6LS), a broadly neutralising antibody, administered every four months combined with monthly intramuscular (IM) long-acting cabotegravir (CAB LA), maintained viral suppression in</description>
</item>
<item>
<title>ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/viiv-healthcare-showcases-long-acting-hiv-innovation-and-potential-of-ultra-long-acting-pipeline-including-new-data-for-first-third-generation-integrase-inhibitor-at-croi-2026</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/viiv-healthcare-showcases-long-acting-hiv-innovation-and-potential-of-ultra-long-acting-pipeline-including-new-data-for-first-third-generation-integrase-inhibitor-at-croi-2026</guid>
<pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
<description>LONDON, February 17, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data presentations from its innovative HIV treatment and prevention portfolio and integrase inhibitor (INSTI)-led pipeline at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado from 22-25 February.</description>
</item>
<item>
<title>Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd.</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/cumulus-neuroscience-enters-japanese-market-to-advance-novel-cognitive-biomarkers-with-new-customer-shionogi-and-co-ltd</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/cumulus-neuroscience-enters-japanese-market-to-advance-novel-cognitive-biomarkers-with-new-customer-shionogi-and-co-ltd</guid>
<pubDate>Tue, 10 Feb 2026 13:00:00 GMT</pubDate>
<description>Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, has entered the Japanese market through a new customer relationship with Shionogi & Co., Ltd. (Shionogi), a major research-driven pharmaceutical company based in Japan.</description>
</item>
<item>
<title>Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/verrica-pharmaceuticals-announces-launch-of-ycanthr-for-the-treatment-of-molluscum-contagiosum-in-japan-by-partner-torii-pharmaceutical</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/verrica-pharmaceuticals-announces-launch-of-ycanthr-for-the-treatment-of-molluscum-contagiosum-in-japan-by-partner-torii-pharmaceutical</guid>
<pubDate>Mon, 09 Feb 2026 13:00:00 GMT</pubDate>
<description>WEST CHESTER, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the launch of YCANTH® in Japan by its partner, Torii Pharmaceutical Co. Ltd. (“Torii”), a wholly-owned subsidiary of Shionogi & Co., Ltd., for the treatment of molluscum contagiosum (“molluscum”). “We would like to congratulate our partner, Torii, on th</description>
</item>
<item>
<title>Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® (edaravone) and IV RADICAVA</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/shionogi-expands-rare-disease-presence-with-planned-acquisition-of-global-rights-to-tanabe-pharma-corporations-radicava-orsr-edaravone-and-iv-radicava</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/shionogi-expands-rare-disease-presence-with-planned-acquisition-of-global-rights-to-tanabe-pharma-corporations-radicava-orsr-edaravone-and-iv-radicava</guid>
<pubDate>Mon, 22 Dec 2025 13:00:00 GMT</pubDate>
<description>OSAKA, Japan, December 22, 2025--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that its Board of Directors, at a meeting held on December 22, 2025, resolved to acquire a newly established company that Tanabe Pharma Corporation (Head Office: Osaka, Japan; Chief Executive Officer: Akihisa Harada; hereafter "Tanabe Pharma") will create to hold the rights to RADICAVA ORS® (edaravone) and IV RADICAVA. Tanabe Pharma pla</description>
</item>
<item>
<title>BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/bioversys-announces-bv100-phase-3-initiation-and-provides-a-business-update-1</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/bioversys-announces-bv100-phase-3-initiation-and-provides-a-business-update-1</guid>
<pubDate>Thu, 11 Dec 2025 06:00:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Art. 53LR BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaborati</description>
</item>
<item>
<title>ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with significantly less weight gain</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/viiv-healthcare-announces-96-week-data-reaffirming-dovato-is-as-effective-as-biktarvy-in-maintaining-virological-suppression-of-hiv-1-with-significantly-less-weight-gain-1</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/viiv-healthcare-announces-96-week-data-reaffirming-dovato-is-as-effective-as-biktarvy-in-maintaining-virological-suppression-of-hiv-1-with-significantly-less-weight-gain-1</guid>
<pubDate>Fri, 17 Oct 2025 11:00:00 GMT</pubDate>
<description>DURHAM, N.C., October 17, 2025--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced 96-week findings from PASO DOBLE (GeSIDA 11720 study) showing that Dovato (dolutegravir/lamivudine [DTG/3TC]) is as effective as Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide fumarate [BIC/FTC/TAF]) in maintaining virological suppression in adults with HIV-1. Individuals taking Dovato also experienced statistically signifi</description>
</item>
<item>
<title>Gareth Morgan Named President of Qpex Biopharma, Inc.</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/gareth-morgan-named-president-of-qpex-biopharma-inc</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/gareth-morgan-named-president-of-qpex-biopharma-inc</guid>
<pubDate>Wed, 15 Oct 2025 12:30:00 GMT</pubDate>
<description>SAN DIEGO, October 15, 2025--Qpex Biopharma, Inc., a Shionogi Group Company (hereafter "Qpex"), announced that Gareth Morgan, MS, MBA, most recently Senior Vice President and Global Head of Portfolio Management and AMR Policy at Shionogi Inc., has been appointed President of Qpex. Morgan succeeds Michael Dudley, Pharm.D., who has retired and stepped down from his role as President and CEO. Dr. Dudley will continue to serve as a strategic advisor to Qpex and Shionogi.</description>
</item>
<item>
<title>ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/viiv-healthcares-clarity-study-shows-long-acting-cabotegravir-more-acceptable-than-lenacapavir-injections-after-a-single-dose-with-90percent-preferring-cabotegravir</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/viiv-healthcares-clarity-study-shows-long-acting-cabotegravir-more-acceptable-than-lenacapavir-injections-after-a-single-dose-with-90percent-preferring-cabotegravir</guid>
<pubDate>Wed, 15 Oct 2025 11:00:00 GMT</pubDate>
<description>LONDON, October 15, 2025--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced data from the phase I CLARITY open-label, crossover study, showing clinically relevant differences in injection site reaction (ISR) acceptability and tolerability, with 69% of HIV-negative adults finding cabotegravir long-acting (CAB LA) injections to be "totally or very acceptable" vs 48% for lenacapavir (LEN) injections. Data presented at</description>
</item>
<item>
<title>ViiV Healthcare showcases breadth of clinical and real-world evidence at EACS and IDWeek 2025</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/viiv-healthcare-showcases-breadth-of-clinical-and-real-world-evidence-at-eacs-and-idweek-2025</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/viiv-healthcare-showcases-breadth-of-clinical-and-real-world-evidence-at-eacs-and-idweek-2025</guid>
<pubDate>Thu, 09 Oct 2025 13:00:00 GMT</pubDate>
<description>LONDON, October 09, 2025--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of more than 60 abstracts, including data from its industry-leading long-acting HIV treatment and prevention portfolio, at the 20th European AIDS Conference (EACS) in Paris, France from 15-18 October, and at IDWeek 2025 in Atlanta, Georgia, US from 19-22 October.</description>
</item>
<item>
<title>Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/verrica-pharmaceuticals-announces-that-development-partner-torii-pharmaceutical-receives-approval-for-ycanthr-to-208-in-japan-for-the-treatment-of-molluscum-contagiosum</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/verrica-pharmaceuticals-announces-that-development-partner-torii-pharmaceutical-receives-approval-for-ycanthr-to-208-in-japan-for-the-treatment-of-molluscum-contagiosum</guid>
<pubDate>Fri, 19 Sep 2025 12:00:00 GMT</pubDate>
<description>– Approval triggers $10 million cash milestone payment to Verrica – – YCANTH® approval in Japan addresses significant unmet need of patients with molluscum – – Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan – WEST CHESTER, Pa., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventi</description>
</item>
<item>
<title>Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/shionogi-to-present-new-data-from-anti-infective-portfolio-at-idweek</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/shionogi-to-present-new-data-from-anti-infective-portfolio-at-idweek</guid>
<pubDate>Wed, 03 Sep 2025 12:30:00 GMT</pubDate>
<description>FLORHAM PARK, N.J., September 03, 2025--Shionogi Inc., a United States subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.), will share 17 scientific presentations from across its anti-infective programs at IDWeek 2025 (October 19-22, 2025) in Atlanta, Georgia.</description>
</item>
<item>
<title>FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/fda-accepts-shionogis-ensitrelvir-nda-as-the-first-oral-therapy-for-the-prevention-of-covid-19-following-exposure</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/fda-accepts-shionogis-ensitrelvir-nda-as-the-first-oral-therapy-for-the-prevention-of-covid-19-following-exposure</guid>
<pubDate>Tue, 02 Sep 2025 12:30:00 GMT</pubDate>
<description>OSAKA, Japan, September 02, 2025--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) from Shionogi Inc., a New Jersey-based subsidiary of Shionogi, for ensitrelvir (Generic name: ensitrelvir fumaric acid, Code No.: S-217622), an investigational oral antiviral for the prevention of COVID-19 following exposure to an infected individual.</description>
</item>
<item>
<title>ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/viiv-healthcare-extends-voluntary-licensing-agreement-with-medicines-patent-pool-to-enable-access-to-innovative-long-acting-injectable-hiv-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/viiv-healthcare-extends-voluntary-licensing-agreement-with-medicines-patent-pool-to-enable-access-to-innovative-long-acting-injectable-hiv-treatment</guid>
<pubDate>Mon, 14 Jul 2025 13:28:00 GMT</pubDate>
<description>LONDON, July 14, 2025--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced an update to their voluntary licensing agreement with the Medicines Patent Pool (MPP) for cabotegravir to include patents relating to its use in a long-acting HIV treatment regimen. The announcement follows updated guidance from WHO recommending long-acting injectable cabotegravir + rilpivirine as an HIV treatment option.</description>
</item>
<item>
<title>Shionogi Implements Stibo Systems MDM Solution</title>
<link>https://6ix.com/company/shionogi-and-co-ltd/news/shionogi-implements-stibo-systems-mdm-solution</link>
<guid isPermaLink="true">https://6ix.com/company/shionogi-and-co-ltd/news/shionogi-implements-stibo-systems-mdm-solution</guid>
<pubDate>Thu, 10 Jul 2025 13:00:00 GMT</pubDate>
<description>Stibo Systems K.K. (headquartered in Aarhus, Denmark; hereinafter "Stibo Systems") is pleased to announce that Shionogi & Co., Ltd. (headquartered in Chuo-ku, Osaka; hereinafter "Shionogi") has implemented its master data management (MDM) solution, "Stibo Systems MDM," in collaboration with Hitachi, Ltd. (headquartered in Chiyoda-ku, Tokyo; hereinafter "Hitachi").</description>
</item>
</channel>
</rss>